Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.70 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.70 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 11/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20905106 | 0.97 | SPHK1 (0.70) | SPHK1SPHK2AHRAPPABCG2 | |
| SCHEMBL13896121 | 0.91 | SPHK1 (0.57) | SPHK1SPHK2AHRNR5A1APP | |
| SCHEMBL20168979 | 0.90 | SPHK1 (0.56) | SPHK1SPHK2AHRNR5A1APP | |
| SCHEMBL23519671 | 0.89 | SPHK1 (0.55) | SPHK1SPHK2AHRNR5A1ABCG2 | |
| SCHEMBL18194576 | 0.86 | SPHK1 (0.52) | SPHK1SPHK2AHRNR5A1ABCG2 | |
| SCHEMBL12450354 | 0.86 | SPHK1 (0.52) | SPHK1SPHK2AHRNR5A1ABCG2 | |
| SCHEMBL12812128 | 0.85 | SPHK1 (0.51) | SPHK1SPHK2AHRNR5A1ABCG2 | |
| SCHEMBL20592376 | 0.82 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL20596127 | 0.82 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL18194573 | 0.82 | SPHK1 (1.00) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024259-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11737992-B2 | Sphingosine kinase Type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11723895-B2 | Sphingosine pathway modulating compounds for the treatment of coronavirus infection | ENZO BIOCHEM, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20210290567-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION | ENZO BIOCHEM, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210177776-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF | ENZO THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210169860-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10945971-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | ENZO THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210000766-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10881643-B2 | Sphingosine pathway modulating compounds for the treatment of cancers | ENZO BIOCHEM, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200230113-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | ENZO BIOCHEM, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-9388121-B2 | Sphingosine kinase type 1 inhibitors | ENZO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20130245321-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS | VIRGINIA COMMONWEALTH UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| US-20130245321-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS | VIRGINIA COMMONWEALTH UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| US-8314151-B2 | Sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314151-B2 | Sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120237448-A9 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-20120237448-A9 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| WO-2011025545-A1 | SPHINGOSINE TYPE 1 INHIBITORS AND METHODS FOR MAKING AND USING SAME | ENZO THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100278741-A1 | Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278741-A1 | Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same | ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237448-A9 | SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4670/4885 |
| US-11723895-B2 | Sphingosine pathway modulating compounds for the treatment of coronavirus infection | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 817/4885 |
| US-20200230113-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 653/4885 |
| US-20210000766-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 653/4885 |
| US-20130245321-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4512/4885 |
| US-10945971-B2 | Sphingosine kinase type 1 inhibitors and uses thereof | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4523/4885 |
| US-20100278741-A1 | Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4633/4885 |
| US-20210177776-A1 | SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4728/4885 |
| US-20210290567-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 817/4885 |
| US-11737992-B2 | Sphingosine kinase Type 1 inhibitors and uses thereof | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885AHR 4728/4885 |
| US-10881643-B2 | Sphingosine pathway modulating compounds for the treatment of cancers | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 653/4885 |
| US-20210169860-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 653/4885 |
| US-20240024259-A1 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | S1PR1, SPHK1, S1PR4 | SPHK1 2/4885SPHK2 7/4885AHR 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.